Covid19
No benefit of low dose apixaban following acute COVID-19 – News Medical
The HEAL-COVID trial compared the efficacy of Apixaban to standard care in adults who have recently recovered from severe COVID-19.
The HEAL-COVID trial compared the efficacy of Apixaban to standard care in adults who have recently recovered from severe COVID-19.
Read more at www.news-medical.net